Journal Article10.1016/j.tcm.2023.02.002
Head-to-head comparison between left atrial appendage occlusion and non-vitamin K oral anticoagulants in non-valvular atrial fibrillation patients: A systematic review and meta-analysis study
01 Feb 2023
6
TL;DR: In this paper , the authors compared the clinical benefits between LAAO and NOAC in non-valvular AF patients, and found that the left atrial appendage occlusion (LAAO) was non-inferior to warfarin.
read more
About: This article is published in Trends in Cardiovascular Medicine. The article was published on 01 Feb 2023. The article focuses on the topics: Medicine & Left atrial appendage occlusion.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Practical Guide on Left Atrial Appendage Closure for the Non-implanting Physician. An International Consensus Paper.
Tatjana Potpara,Marek Grygier,Karl Georg Haeusler,Jens Erik Nielsen-Kudsk,Sergio Berti,Simonetta Genovesi,E. Marijon,Serge Boveda,Apostolos Tzikas,G. Boriani,L. Boersma,C. Tondo,Tom de Potter,G. Lip,Renate B Schnabel,R. Bauersachs,Marco Senzolo,Carlo Basile,Stefano Bianchi,Pavel Osmancik,Boris Schmidt,U. Landmesser,Wolfram Doehner,Gerhard Hindricks,Jan Kovac,A. John Camm +25 more
TL;DR: Left atrial appendage closure, predominantly achieved using a catheter-based, device implantation approach, is increasingly favoured for the prevention of thromboembolic events in patients who cannot achieve effective anticoagulation.
14
Index-Guided High-Power Radiofrequency Catheter Ablation for Atrial Fibrillation: A Systematic Review and Meta-Analysis Study.
Yoga Waranugraha,Chia Ti Tsai,Lian-Yu Lin +2 more
TL;DR: The IGHP RFCA is an effective and efficient strategy for AF ablation and includes the shorter procedure time, shorter RF application time, fewer number of lesions for complete PVI, and more excellent first-pass PVI.
2
Novel scoring system derived from meta-analysis and validated in cohort population for predicting 1-year atrial fibrillation recurrence after cryoballoon catheter ablation: The HeLPS-Cryo score.
Yoga Waranugraha,Jung-Chi Hsu,Li-Ting Ho,Chih-Chieh Yu,Yen-Bin Liu,Lian-Yu Lin +5 more
- 24 Feb 2024
TL;DR: The HeLPS-Cryo score can help the physician estimate the probability of 1-year AF recurrence after the successful CBCA procedure and develop a new scoring system based only on pre-procedural parameters.
1
A Systematic Review and Meta-Analysis of Randomised Controlled Trials Assessing Clinical and Haemodynamic Outcomes of Ivabradine in Heart Failure With Reduced Ejection Fraction Patients
Yoga Waranugraha,Ardian Rizal,Cholid Tri Tjahjono,Irene Yasmina Vilado,Nathanael Ibot David,Fikri Abudan,Dwi Ayu Setyaningrum +6 more
TL;DR: A systematic review and meta-analysis of randomised controlled trials assessed clinical and haemodynamic outcomes of ivabradine in HFrEF patients. Ivabradine can improve clinical and haemodynamic outcomes in HFrEF patients.
1
Left Atrial Appendage Occlusion for Prevention of Thromboembolism in Atrial Fibrillation: Is it Ready for First Line Therapy?
Deepak Bhakta,M N Sharif +1 more
TL;DR: In this article , the authors discuss the current role of the ECG in the diagnosis and management of CA, focusing on the most common ECG abnormalities and rhythm disorders, and great awareness is needed to increase diagnostic performance and improve patient's outcome.
References
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page,Joanne E. McKenzie,Patrick M.M. Bossuyt,Isabelle Boutron,Tammy Hoffmann,Cynthia D. Mulrow,Larissa Shamseer,Jennifer Tetzlaff,Elie A. Akl,Sue E. Brennan,Roger Chou,Julie Glanville,Jeremy M. Grimshaw,Asbjørn Hróbjartsson,Manoj M. Lalu,Tianjing Li,Elizabeth Loder,Evan Mayo-Wilson,Steve McDonald,Luke A McGuinness,Lesley A. Stewart,James Thomas,Andrea C. Tricco,Vivian Welch,Penny Whiting,David Moher +25 more
TL;DR: The preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement as discussed by the authors was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found.
46.2K
RoB 2: a revised tool for assessing risk of bias in randomised trials.
Jonathan A C Sterne,Jelena Savović,Jelena Savović,Matthew J. Page,Roy G Elbers,Natalie S Blencowe,Isabelle Boutron,Isabelle Boutron,Isabelle Boutron,Christopher J Cates,Hung-Yuan Cheng,Mark Corbett,Sandra Eldridge,Jonathan Emberson,Miguel A. Hernán,Sally Hopewell,Asbjørn Hróbjartsson,Asbjørn Hróbjartsson,Daniela R Junqueira,Peter Jüni,Jamie J Kirkham,Toby J Lasserson,Tianjing Li,Alexandra McAleenan,Barnaby C Reeves,Sasha Shepperd,Ian Shrier,Lesley A. Stewart,Kate Tilling,Ian R. White,Penny Whiting,Penny Whiting,Julian P T Higgins,Julian P T Higgins +33 more
TL;DR: The Cochrane risk-of-bias tool has been updated to respond to developments in understanding how bias arises in randomised trials, and to address user feedback on and limitations of the original tool.
19.6K
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.
Jonathan A C Sterne,Miguel A. Hernán,Barnaby C Reeves,Jelena Savović,Jelena Savović,Nancy D. Berkman,Meera Viswanathan,David Henry,Douglas G. Altman test,Mohammed T. Ansari,Isabelle Boutron,James R. Carpenter,An-Wen Chan,Rachel Churchill,Jonathan J Deeks,Asbjørn Hróbjartsson,Jamie J Kirkham,Peter Jüni,Yoon K. Loke,Theresa D Pigott,Craig R Ramsay,Deborah L. Regidor,Hannah R. Rothstein,Lakhbir Sandhu,Pasqualina Santaguida,Holger J. Schünemann,Beverly Shea,Ian Shrier,Peter Tugwell,Lucy Turner,Jeffrey C. Valentine,Hugh Waddington,Elizabeth Waters,George A. Wells,Penny Whiting,Julian P T Higgins +35 more
TL;DR: Risk of Bias In Non-randomised Studies - of Interventions is developed, a new tool for evaluating risk of bias in estimates of the comparative effectiveness of interventions from studies that did not use randomisation to allocate units or clusters of individuals to comparison groups.
Dabigatran versus warfarin in patients with atrial fibrillation
Stuart J. Connolly,Michael D. Ezekowitz,John W. Eikelboom,Jonas Oldgren,Amit Parekh,Janice Pogue,Paul A. Reilly,Ellison Themeles,Jeanne Varrone,Susan Wang,Marco Alings,Denis Xavier,Jun Zhu,Rafael Diaz,Basil S. Lewis,Harald Darius,Hans-Christoph Diener,Campbell D. Joyner,Lars Wallentin +18 more
TL;DR: In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.